Case Scenario 4: Endometrial Carcinoma - Full Discussion

1. Most Likely Diagnosis

2. Risk Factors

3. Role of Unopposed Estrogen in Pathogenesis

• In obesity, adipose tissue contains the enzyme aromatase, which converts adrenal androgens (androstenedione) into estrone - a biologically active estrogen. Obese postmenopausal women therefore have persistently elevated circulating estrogen with no balancing progesterone (since they are anovulatory/postmenopausal).
• This drives continuous proliferation of the endometrial glands.
• Over time, the proliferating epithelium accumulates somatic mutations (in PTEN, KRAS, PIK3CA, ARID1A, MLH1, etc.), progressing stepwise:

Normal endometrium → Simple hyperplasia → Complex hyperplasia → Atypical complex hyperplasia (the true precursor) → Endometrioid carcinoma

• PI3K/AKT signaling, which is augmented by estrogen receptor-dependent pathways, is the molecular hallmark of endometrioid carcinoma. Multiple successive mutations in PTEN, PIK3CA, and KRAS all converge on this pathway, progressively amplifying proliferative signaling.

4. Precursor Lesions of Endometrial Carcinoma

Endometrial Hyperplasia - classified by cytologic atypia:

• Atypical complex hyperplasia (EIN - Endometrial Intraepithelial Neoplasia) is the recognized direct precursor. Studies of hysterectomy specimens containing both atypical hyperplasia and carcinoma show identical mutations in PTEN, ARID1A, PIK3CA, and KRAS in both components - confirming the precursor relationship and the fact that mutations begin before overt carcinoma is present.

• The precursor is Serous Endometrial Intraepithelial Carcinoma (SEIC) - a noninvasive lesion arising on a background of atrophic endometrium (the opposite of Type I), with early TP53 mutations.

5. Treatment for Early-Stage Disease

Standard Treatment: Surgical Staging + Hysterectomy

1. Total extrafascial hysterectomy + bilateral salpingo-oophorectomy (BSO)
   • This is the cornerstone of treatment for Stage I disease.
   • Radical hysterectomy does NOT improve survival over simple hysterectomy + BSO and adds unnecessary morbidity - it should not be performed for apparent early disease.
2. Surgical staging - includes:
   • Peritoneal washings
   • Pelvic and para-aortic lymph node assessment (sentinel node biopsy is now standard)
   • Inspection for peritoneal/adnexal metastases
   • Lymph node involvement defines Stage IIIC disease
3. Approach:
   • Minimally invasive surgery (laparoscopic or robotic-assisted) is preferred, especially in obese patients (like this patient), and shows equivalent oncologic outcomes to laparotomy (GOG trial: 3-year recurrence 11.4% laparoscopy vs. 10.2% open; 5-year survival 90% in both arms).

Adjuvant Therapy by Risk Category (Stage I):

All endometrial cancers should be routinely tested for microsatellite instability (MSI) - MSI-high tumors (often associated with Lynch syndrome) respond to PD-1 checkpoint inhibitors when recurrent or advanced.

Histopathology Grades (for reference):

Clinical Scenario 5: Endometrial Carcinoma - Full Discussion

Case Summary

1. Most Likely Diagnosis

2. Risk Factors Present in This Patient

Nulliparity

Tamoxifen Therapy (6 years)

Note: Raloxifene (another SERM) does not carry this risk, as it lacks estrogenic activity in the endometrium.

3. Why is Postmenopausal Bleeding an Important Warning Symptom?

1. High association with endometrial malignancy: Approximately 10% of women with PMB have endometrial carcinoma. In women with additional risk factors (as in this case), this probability is significantly higher.
2. Endometrium should be quiescent: After menopause, estrogen levels drop and the endometrium becomes atrophic. Any bleeding indicates abnormal stimulation - either from a hormonal source, an anatomic lesion, or malignancy.
3. Early presentation of cancer: Endometrial carcinoma fortunately tends to cause bleeding early (even before deep invasion), making PMB a useful early warning. Most women present at Stage I, contributing to the relatively good overall prognosis of this cancer.
4. Other causes must also be excluded: Atrophic vaginitis (most common), endometrial polyps, submucosal fibroids, and exogenous estrogen use - but malignancy must always be ruled out first.

4. Role of Transvaginal Ultrasonography (TVUS) in Evaluating PMB

Endometrial Thickness Measurement

• In postmenopausal women not on HRT, a normal endometrial stripe should be ≤4 mm.
• Thickness >4-5 mm requires further investigation (endometrial biopsy).
• In women on tamoxifen, the threshold is less clear because tamoxifen causes subendometrial changes that artificially thicken the apparent endometrial stripe; biopsy is recommended regardless of thickness in symptomatic tamoxifen users.
• This patient's 16 mm with irregular lining is markedly abnormal and strongly suspicious for malignancy.
• Meta-analysis data show that 96% of women with endometrial cancer had an endometrial stripe >5 mm on TVUS. - Swanson's Family Medicine Review

Additional TVUS Findings

• Endometrial morphology: irregular, heterogeneous, polypoid lesions raise suspicion
• Myometrial invasion: can be estimated (though MRI is superior for this)
• Adnexal masses or ovarian pathology
• Uterine size and contour

Limitations

• Cannot definitively diagnose or grade endometrial carcinoma - tissue biopsy is still required
• Limited in obese patients (transvaginal approach improves this)
• Tamoxifen users have subendometrial cysts that make thickness measurement unreliable

5. Gold Standard Investigation for Confirming the Diagnosis

Methods:

1. Office endometrial aspiration/pipelle biopsy - first-line, outpatient procedure
   • Sensitivity ~90% for endometrial carcinoma when adequate tissue obtained
   • Accepted as the standard first step in evaluating abnormal uterine bleeding
   • - Berek & Novak's Gynecology (KEY POINTS)
2. Hysteroscopy-directed biopsy / D&C (dilatation and curettage)
   • Performed when office biopsy is inadequate, inconclusive, or technically difficult
   • Hysteroscopy allows direct visualization of the endometrial cavity
   • More sensitive than blind sampling

What Biopsy Provides:

• Histological type (endometrioid, serous, clear cell, etc.)
• Grade (G1 = well differentiated, G2 = moderate, G3 = poorly differentiated)
• Presence of atypical features or precursor lesions

Role of MRI (Staging Imaging - Not Diagnostic)

• Depth of myometrial invasion (<50% = Stage IA vs. ≥50% = Stage IB)
• Cervical stromal invasion (Stage II)
• Parametrial/adnexal involvement (Stage III)
• Lymph node status

6. Standard Treatment for This Stage (FIGO Stage IA Endometrioid Carcinoma)

Primary Treatment: Surgery

1. Total hysterectomy + BSO - removes the primary tumor and eliminates the source of estrogen (ovaries)
2. Peritoneal washings for cytology
3. Sentinel lymph node biopsy (now standard at most centers) - provides staging without full lymphadenectomy
   • Lymph node involvement upgrades to Stage IIIC and mandates systemic therapy

Radical hysterectomy (with parametrial resection) does not improve survival over simple hysterectomy in Stage I disease and should NOT be performed. - Berek & Novak's Gynecology, p. 2176

Surgical Approach

• Minimally invasive (laparoscopic or robotic-assisted) is preferred
• Equivalent oncologic outcomes to open surgery (GOG trial: 5-year survival 90% in both arms)
• Robotic approach is especially useful in obese patients, offering reduced blood loss, shorter hospital stay, and higher lymph node yields

Adjuvant Therapy by Risk (Stage IA):

Important Additional Considerations:

• Stop tamoxifen - this is essential. She should be switched to an aromatase inhibitor for her breast cancer (which, unlike tamoxifen, reduces endometrial stimulation).
• MSI/MMR testing: All endometrial cancers should now routinely be tested for microsatellite instability. MSI-high tumors (Lynch syndrome or sporadic) qualify for pembrolizumab (PD-1 inhibitor) if recurrence occurs.
• Her anemia (Hb 9.8 g/dL) from chronic blood loss should be addressed preoperatively.

Summary Table